Pain Therapeutics, Inc. has received a Complete Response Letter from the U.S. FDA for its New Drug Application for REMOXY, an abuse-resistant controlled-release form of oxycodone. Based on its review, the FDA has determined that the NDA is not approved in its present form.
The details can be read here.
No comments:
Post a Comment